Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


Contact us

Phone: +44 (0)1865 857240


ISAP examines the effects of oral semaglutide, a glucagon-like protein-1 receptor agonist used for diabetes, on the build-up of proteins in the brain characterising Alzheimer’s Disease (amyloid and tau), brain inflammation, and people’s memory and thinking abilities. People included in ISAP are at higher risk of developing Alzheimer’s Disease because of having the protein amyloid in their brains.


One-year randomised, double-blind, placebo-controlled, parallel-group, superiority trial led through a collaboration between the Diabetes Trials Unit and the Department of Psychiatry at the University of Oxford, and the global healthcare company, Novo Nordisk. ISAP will recruit 88 volunteers with high brain amyloid (so-called ‘amyloid-positive’) currently living without dementia from 5 UK clinical sites in Oxford, London (Imperial College and University College), Exeter and Bristol.



  • To explore the effect of semaglutide on the rate of accumulation of tau protein in the brain.


  • To explore other potential mechanisms of action and effects of semaglutide on the pathway for Alzheimer’s disease including neuroinflammation, biomarkers in blood for Alzheimer’s disease, memory, thinking ability, neurodegeneration, health-related quality of life, levels of physical activity, and circadian rhythms.



Chief Investigator Ivan Koychev

Amanda I. Adler

Rury R. Holman

Sponsor University of Oxford
Funder Novo Nordisk A/S
Reference number EudraCT 2021-003328-34
Trial Manager

Charlotte Woodward